NrtI

Phase 2Small molecule

VVir Biotechnology, Inc.

NrtI is one of 28 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatitis D, ChronicActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Hepatitis D, ChronicPhase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 3

Incivek

Vertex Pharmaceuticals

Preclinical

10 4

Intron a

Sanofi

Preclinical

7 5

Roferon-a

Roche

Preclinical

3 6

Medrol

Pfizer

Preclinical

1 7

Dasabuvir

AbbVie

Preclinical

7 8

NrtI

VVir Biotechnology, Inc.

Phase 2

1 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 2Active, not recruiting

Hepatitis D, Chronic

NCT05461170

Clinical

Trials by Indication[1]

Chronic Hepatitis1 trial

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Terminated·AAssembly Biosciences·Phase 2·NCT04454567·2 enrolled

Renal Impairment1 trial

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Completed· Gilead logo

Gilead·Phase 3·NCT01363011·106 enrolled

Hepatitis D, Chronic1 trial

A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)

Active, not recruiting·VVir Biotechnology, Inc.·Phase 2·NCT05461170·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NrtI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NrtI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NrtI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vir Biotechnology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVir Biotechnology, Inc.

NrtI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Chronic Hepatitis1 trial

Renal Impairment1 trial

Hepatitis D, Chronic1 trial

References

Drug Info

Quick Facts

Related News